ClinicalTrials.gg
RecruitingNCT07500012Updated Mar 30, 2026

taVNS for Breast Cancer Pain and Symptom Management

An interventional study of Active taVNS and Sham taVNS in Breast Cancer Survivors, sponsored by Florida State University. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Florida State University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Pain by Florida State University — 3 open to participants now, 3 under way, none of them phase 3. Pain · Florida State University.

Planned enrollment
13th of 14
40 · median 99
Started
2026
with 2 others
No phase
14 of 14
3 open now
Registered
13th of 14
by date

Among the 14 studies in Pain by Florida State University, this one is the 13th largest by planned enrollment, is one of 3 that started in 2026, is one of 14 with no phase, and was the 13th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

3 of the 14 studies in Pain by Florida State University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years to 79 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Pain by Florida State University, or all of them as a file.
02

Study summary

  1. To evaluate the feasibility and acceptability of a home-based taVNS intervention and follow-up for pain and symptom management in breast cancer survivors.
  2. To investigate the impact of taVNS on secondary outcomes, including pain, anxiety, depression, fatigue, and the brain-gut axis (BGA) in breast cancer survivors.
03

Conditions studied

  • Breast Cancer Survivors

Browse trials for

Keywords

  • pain
  • symptoms
  • transcutaneous auricular vagus nerve stimulation (taVNS)
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. are aged 18-79 years older;
  2. have confirmed Stage 0, I, II, or III breast cancer;
  3. had completed their primary cancer treatment (surgery, radiotherapy, chemotherapy) and are currently on a stable survivorship care plan (e.g., endocrine therapy, supportive care), with no major treatment changes expected during the study;
  4. have experienced pain with a severity of 4 or greater out of 10 for at least ten days in the last month;
  5. are committed to maintaining the current treatment plan (e.g., endocrine therapy, supportive care) during the study;
  6. have reliable internet access;
  7. are willing to provide stool samples and undergo fNIRS brain imaging procedures;
  8. are able to read and understand English and provide written .

Exclusion criteria

Exclusion Criteria:

  1. have breast cancer (Stage IV);
  2. have a current diagnosis of another active cancer;
  3. have a history of significant cardiac conditions, such as bradycardia, arrhythmia, recent myocardial infarction, or heart failure;
  4. have been diagnosed with a severe psychiatric illness (e.g., schizophrenia, bipolar I disorder with active psychosis) that could interfere with adherence to study procedures;
  5. have active inflammatory or malabsorptive gastrointestinal disorders (e.g., Crohn's disease, ulcerative colitis, celiac disease) that could confound gut microbiota results;
  6. have taken antibiotics, probiotics, or gastrointestinal motility agents (e.g., laxatives, prokinetics) within the past 3 months, due to potential disruption of gut microbiota;
  7. have a progressive neurological condition (e.g., Parkinson's disease, epilepsy, multiple sclerosis) that may impact fNIRS data quality or study participation;
  8. have a history of surgical or pharmacological vagotomy or are currently receiving implanted vagus nerve stimulation therapy, because of potential interference with autonomic regulation and taVNS mechanisms;
  9. have an active electronic or metallic implant (e.g., cochlear implant, pacemaker, neurostimulator) or other electronic/metallic device in the head or neck area, which may be for taVNS;
  10. are pregnant, breastfeeding, or planning to become pregnant during the study period;
  11. have had a recent initiation or dose change of pain medications (e.g., opioids, neuropathic agents) within the past 4 weeks.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Active taVNS intervention

    practice the active taVNS twice daily for 30 minutes each over a 4-week period (56 sessions)

    Device: Active taVNS

  • Sham comparator
    Sham taVNS

    practice the sham taVNS twice daily for 30 minutes each over a 4-week period (56 sessions)

    Device: Sham taVNS

Interventions

  • DeviceActive taVNS

    practice the active taVNS twice daily for 30 minutes each over a 4-week period (56 sessions)

  • DeviceSham taVNS

    practice the sham taVNS twice daily for 30 minutes each over a 4-week period (56 sessions)

06

What researchers measure

Primary outcomes

  1. Feasibility of implementing taVNS - Retention rates

    Feasibility will be assessed by evaluating the retention rate of participants who complete the taVNS sessions at 4 weeks and the follow-up at week 8. Retention rates will be calculated by comparing the number of participants who complete these timepoints with the baseline data.

    Time frame: Baseline and 4 weeks and 8 weeks

  2. Adherence of implementing taVNS - Duration of usage

    Participants will log the frequency, time, and duration of daily taVNS device use in an online diary through the REDCap system.

    Time frame: 4 weeks

  3. Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)

    Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) in using the taVNS will be measured using self-reported data, including online self-monitoring diary, surveys, and interviews. Adverse events (AEs) will be monitored daily using the online diary with a preset form, including a 10-item survey to assess daily AEs of taVNS on 0-10 Likert scales.

    Time frame: Baseline and 4 weeks and 8 weeks

  4. Satisfaction in implementing taVNS

    Satisfaction in using the taVNS will be measured using self-reported data including online self-monitoring diary, surveys, and interviews.

    Time frame: Baseline and 4 weeks and 8 weeks

Secondary outcomes

  1. Change in pain intensity and interference

    Pain Inventory (BPI) will be used to assess the multidimensional aspects of pain, its location, intensity, and interference. A higher score indicated higher pain intensity with 0 indicating no pain and 10 indicating the worst pain. A higher score of pain interference means daily functions are more impacted by pain, and 0 indicates no pain interference, and 10 means the worst pain interference.

    Time frame: Baseline and 4 weeks and 8 weeks

  2. Change in chronic pain self-efficacy

    Chronic Pain Self-Efficacy Scale (CPSES) will be used to measure pain self-efficacy with scores from 0-100, higher scores indicating improved self-efficacy.

    Time frame: Baseline and 4 weeks and 8 weeks

  3. Changes in quantitative sensory testing (QST)

    Quantitative sensory testing (QST) will be used to measure sensitivity to experimental pain with standardized stimuli to test both nociceptive and non-nociceptive systems.

    Time frame: Baseline and 4 weeks and 8 weeks

  4. Changes in conditioned pain modulation (CPM)

    CPM will be used to determine the net effect of various facilitating and inhibiting systems exerting their activity at spinal or supraspinal levels. A phasic noxious stimulus (cold) will be applied in conjunction with a tonic noxious conditioning stimulus (pressure) applied to a distant body site on the forearm. Participants' self-reported pain intensity by NRS during the test will be recorded.

    Time frame: Baseline and 4 weeks and 8 weeks

  5. Changes in symptoms: Physical Function

    The Patient-Reported Outcomes Measurement Information System (PROMIS) profile will be used to measure the physical function. The T-score of PROMIS measurement ranges from 0 to 100 and a higher T-score indicates a more severe symptom reported by the subjects. A T-score greater than 50 means participants have more severe symptoms than the healthy population.

    Time frame: Baseline and 4 weeks and 8 weeks

  6. Changes in symptoms: Anxiety

    The Patient-Reported Outcomes Measurement Information System (PROMIS) profile will be used to measure the anxiety. The T-score of PROMIS measurement ranges from 0 to 100 and a higher T-score indicates a more severe symptom reported by the subjects. A T-score greater than 50 means participants have more severe symptoms than the healthy population.

    Time frame: Baseline and 4 weeks and 8 weeks

  7. Changes in symptoms: Depression

    The Patient-Reported Outcomes Measurement Information System (PROMIS) profile will be used to measure the co-occurring depression. The T-score of PROMIS measurement ranges from 0 to 100 and a higher T-score indicates a more severe symptom reported by the subjects. A T-score greater than 50 means participants have more severe symptoms than the healthy population.

    Time frame: Baseline and 4 weeks and 8 weeks

  8. Changes in symptoms: Fatigue

    The Patient-Reported Outcomes Measurement Information System (PROMIS) profile will be used to measure the co-occurring fatigue. The T-score of PROMIS measurement ranges from 0 to 100 and a higher T-score indicates a more severe symptom reported by the subjects. A T-score greater than 50 means participants have more severe symptoms than the healthy population.

    Time frame: Baseline and 4 weeks and 8 weeks

  9. Changes in symptoms: Sleep Disturbance

    The Patient-Reported Outcomes Measurement Information System (PROMIS) profile will be used to measure the co-occurring sleep disturbance. The T-score of PROMIS measurement ranges from 0 to 100 and a higher T-score indicates a more severe symptom reported by the subjects. A T-score greater than 50 means participants have more severe symptoms than the healthy population.

    Time frame: Baseline and 4 weeks and 8 weeks

  10. Changes in symptoms: Ability to Participate in Social Roles and Activities

    The Patient-Reported Outcomes Measurement Information System (PROMIS) profile will be used to measure the the ability to participate in social roles and activities. The T-score of PROMIS measurement ranges from 0 to 100 and a higher T-score indicates a more severe symptom reported by the subjects. A T-score greater than 50 means participants have more severe symptoms than the healthy population.

    Time frame: Baseline and 4 weeks and 8 weeks

  11. Changes in pain-related cortical response

    Cortical activity associated with pain stimuli will be assessed utilizing a continuous-wave, multichannel functional near-infrared spectroscopy (fNIRS) imaging system (LIGHTNIRS, Shimadzu, Kyoto, Japan) equipped with three semiconductor lasers emitting at 780, 805, and 830 nm. Optical data will be gathered while subjects undergo thermal pain stimulation.

    Time frame: Baseline and 4 weeks and 8 weeks

  12. Measurement and comparison of fecal microbiota alpha diversity, beta diversity, and abundance of microbial taxa in the human gut

    The 16S rRNA V4 region will be amplified and sequenced by using stool samples to depict the fecal microbiota alpha diversity, beta diversity, and abundance of microbial taxa in the human gut.

    Time frame: Baseline and 4 weeks and 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Deidentified data will be available upon reasonable request. Requests to access these datasets should be directed to jc22db@fsu.edu.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2027, 22 months after the start.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 22 months is above that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2026
First posted
Mar 30, 2026
StartActual
Feb 24, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Feb 2028
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07500012
Responsible party
Jie Chen, PhD, RN (Principal Investigator, Florida State University) — Principal investigator
First posted
Mar 30, 2026
Start date
Feb 24, 2026
Primary completion
Dec 2027 (estimated)
Completion
Feb 2028 (estimated)
Last update
Mar 30, 2026

Study contacts

Jie Chen
Contact
jc22db@fsu.edu
850-645-0657

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion